Paper40201353
Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report.
Li X and 7 others. Front Oncol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report. Papers, record 40201353. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40201353
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References15
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33651422 | First case of lenvatinib-induced pyoderma gangrenosum: Possible management with dose reduction. | J Dermatol | 2021 | https://conductscience.org/library/papers/33651422 | PubMed |
| 2 | 29192996 | British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. | Br J Dermatol | 2017 | https://conductscience.org/library/papers/29192996 | PubMed |
| 3 | 16990857 | Mechanisms of cutaneous toxicities to EGFR inhibitors. | Nat Rev Cancer | 2006 | https://conductscience.org/library/papers/16990857 | PubMed |
| 4 | 38039993 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/38039993 | PubMed |
| 5 | 29433850 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | Lancet | 2018 | https://conductscience.org/library/papers/29433850 | PubMed |
| 6 | 28589639 | Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. | J Gastroenterol Hepatol | 2018 | https://conductscience.org/library/papers/28589639 | PubMed |
| 7 | 22004366 | Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. | J Gastroenterol Hepatol | 2012 | https://conductscience.org/library/papers/22004366 | PubMed |
| 8 | 38650037 | Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. | BMC Med | 2024 | https://conductscience.org/library/papers/38650037 | PubMed |
| 9 | 37426368 | Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma. | Dermatol Reports | 2023 | https://conductscience.org/library/papers/37426368 | PubMed |
| 10 | 32272980 | Autoimmune bullous skin diseases, pemphigus and pemphigoid. | J Allergy Clin Immunol | 2020 | https://conductscience.org/library/papers/32272980 | PubMed |
| 11 | 34282745 | Tyrosine kinase inhibitors-associated pyoderma gangrenosum, a systematic review of published case reports. | Anticancer Drugs | 2022 | https://conductscience.org/library/papers/34282745 | PubMed |
| 12 | 37438964 | Lenvatinib-induced pyoderma gangrenosum in a patient with hepatocellular carcinoma: A case report. | J Dermatol | 2024 | https://conductscience.org/library/papers/37438964 | PubMed |
| 13 | 28155175 | Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. | Endocrine | 2017 | https://conductscience.org/library/papers/28155175 | PubMed |
| 14 | 30236834 | Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. | J Hepatol | 2018 | https://conductscience.org/library/papers/30236834 | PubMed |
| 15 | 31498102 | Pemphigus. | Lancet | 2019 | https://conductscience.org/library/papers/31498102 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42819029 | Case Report: Lenvatinib-induced lichenoid drug reaction mimicking disseminated zoster in a patient with metastatic hepatocellular carcinoma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42819029 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40201353
GET https://conductscience.org/api/papers/v1/40201353/authors